WHO clears 2 kg infant malaria drug as UAE hospitals face imported-case risk

World Health Organization (WHO) prequalified on 24 April 2026 the first malaria treatment for babies weighing 2 kg to 5 kg, a procurement change that should push UAE hospitals to update imported-malaria protocols before peak summer travel.

For UAE COOs, medical directors and laboratory leads, the near-term issue is protocol readiness. WHO certified the UAE malaria-free in 2007, but imported cases still reach emergency departments, paediatrics, obstetrics and infectious disease teams through travel-linked fever presentations.

What changed for infant treatment

The newly prequalified medicine is artemether-lumefantrine in a formulation made for the youngest malaria patients. WHO said procurement agencies can now buy a quality-assured product for babies who weigh 2 kg to 5 kg. Before the 24 April 2026 decision, clinicians often used formulations made for older children, which WHO said increased the risk of dosing errors, side effects and toxicity.

WHO linked the decision to a treatment gap affecting about 30 million babies born each year in malaria-endemic areas of Africa. In the UAE, the operational question is narrower: can paediatric emergency teams identify a febrile infant with recent travel or household travel links, then move quickly to confirmed diagnosis, age-appropriate dosing advice and regulator notification?

"Now we can. Now we must," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.

Diagnostic rules are moving too

WHO also prequalified three new rapid diagnostic tests on 14 April 2026. The tests target pf-LDH, a parasite protein used when Plasmodium falciparum strains evade common HRP2-based rapid tests. WHO cited studies and surveys in 46 countries where some P. falciparum parasites have lost the gene that produces HRP2.

The operational risk is a false-negative malaria test in a patient whose travel history points to infection. WHO said some countries in the Horn of Africa missed up to 80% of cases when HRP2-based tests failed. WHO recommends switching to alternative rapid diagnostic tests when more than 5% of cases are missed because of pf-hrp2 deletions.

• COOs should check whether malaria appears in emergency travel-history triage, isolation procedures and notifiable-disease workflows.
• Medical directors should review infant dosing guidance for suspected or confirmed malaria in patients under 5 kg.
• Laboratory heads should confirm when microscopy, antigen testing or referral testing is required after a negative rapid test.
• CFOs should expect limited case volume in the UAE, but delayed diagnosis can mean ICU admission, longer stays and regulatory reporting exposure.

What UAE operators should check

The UAE malaria-free status does not remove provider obligations. Ministry of Health and Prevention (MOHAP) has said the post-declaration plan depends on early detection and treatment of imported cases, workforce training and mosquito-control vigilance. Department of Health Abu Dhabi (DOH) malaria guidance for healthcare professionals states that the UAE has been malaria-free since 2007, while reported cases are mostly imported P. vivax and P. falciparum.

Dubai Health Authority (DHA) standards list malaria among notifiable communicable diseases, which makes reporting discipline a compliance issue and a clinical issue. For a Dubai hospital, a suspected imported case must move through DHA notification channels. In Abu Dhabi and Al Ain, DOH guidance governs the clinical pathway. In Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah, MOHAP is the main regulator for private healthcare facilities.

Global malaria pressure explains why a rare UAE presentation still deserves board-level attention. WHO's 24 April 2026 announcement cited 282 million malaria cases and 610,000 deaths in 2024, both up from 2023. WHO also said 47 countries have been certified malaria-free and 25 countries are rolling out malaria vaccines.

The concrete takeaway for UAE healthcare operators is a 2026 protocol check across emergency, paediatric and laboratory teams. The new WHO prequalifications will matter most when a small infant arrives with fever, a recent travel history and a negative first-line rapid test.